Gary T Jennings

Summary

Affiliation: Cytos Biotechnology AG
Country: Switzerland

Publications

  1. pmc A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice
    Gunther Spohn
    Cytos Biotechnology, Schlieren, Switzerland
    Virol J 7:146. 2010
  2. doi Immunodrugs: therapeutic VLP-based vaccines for chronic diseases
    Gary T Jennings
    Cytos Biotechnology AG, Zurich Schlieren 8952, Switzerland
    Annu Rev Pharmacol Toxicol 49:303-26. 2009
  3. doi Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis
    Gunther Spohn
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    Eur J Immunol 38:877-87. 2008
  4. doi Combined vaccination against IL-5 and eotaxin blocks eosinophilia in mice
    Yu Zou
    Cytos Biotechnology AG, Wagistrasse 25, CH 8952 Zurich, Schlieren, Switzerland
    Vaccine 28:3192-200. 2010
  5. pmc Therapeutic vaccines for chronic diseases: successes and technical challenges
    Martin F Bachmann
    Cytos Biotechnology AG, Wagistrasse 25, 8952 Zuerich Schlieren, Switzerland
    Philos Trans R Soc Lond B Biol Sci 366:2815-22. 2011
  6. doi A virus-like particle-based anti-nerve growth factor vaccine reduces inflammatory hyperalgesia: potential long-term therapy for chronic pain
    Till A Röhn
    Cytos Biotechnology AG, Immunodrugs, Zurich, Switzerland
    J Immunol 186:1769-80. 2011
  7. doi Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study
    Alain C Tissot
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    Lancet 371:821-7. 2008
  8. ncbi The coming of age of virus-like particle vaccines
    Gary T Jennings
    Cytos Biotechnology AG, CH 8952 Zurich Schlieren, Switzerland
    Biol Chem 389:521-36. 2008
  9. doi A VLP-based vaccine against interleukin-1α protects mice from atherosclerosis
    Alain C Tissot
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    Eur J Immunol 43:716-22. 2013
  10. ncbi A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity
    Patrik Maurer
    Cytos Biotechnology AG, Zurich, Switzerland
    Eur J Immunol 35:2031-40. 2005

Collaborators

Detail Information

Publications18

  1. pmc A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice
    Gunther Spohn
    Cytos Biotechnology, Schlieren, Switzerland
    Virol J 7:146. 2010
    ..Although these vaccines were shown to protect from disease in animal models, multiple injections and/or strong adjuvants were required to reach efficacy, underscoring the need for more immunogenic, yet safe DIII-based vaccines...
  2. doi Immunodrugs: therapeutic VLP-based vaccines for chronic diseases
    Gary T Jennings
    Cytos Biotechnology AG, Zurich Schlieren 8952, Switzerland
    Annu Rev Pharmacol Toxicol 49:303-26. 2009
    ..Safety study designs have considered the underlying B and T cell immunology and have examined potential toxicities of vaccine components and primary and secondary pharmacodynamic action of the vaccines...
  3. doi Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis
    Gunther Spohn
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    Eur J Immunol 38:877-87. 2008
    ....
  4. doi Combined vaccination against IL-5 and eotaxin blocks eosinophilia in mice
    Yu Zou
    Cytos Biotechnology AG, Wagistrasse 25, CH 8952 Zurich, Schlieren, Switzerland
    Vaccine 28:3192-200. 2010
    ..Simultaneous immunization against IL-5 and eotaxin demonstrates that such a therapeutic approach may be used to treat complex disorders in which multiple mediators are involved...
  5. pmc Therapeutic vaccines for chronic diseases: successes and technical challenges
    Martin F Bachmann
    Cytos Biotechnology AG, Wagistrasse 25, 8952 Zuerich Schlieren, Switzerland
    Philos Trans R Soc Lond B Biol Sci 366:2815-22. 2011
    ..Here, we discuss several examples of vaccines that target these risk factors with the aim of preventing the associated diseases and some of the challenges they face...
  6. doi A virus-like particle-based anti-nerve growth factor vaccine reduces inflammatory hyperalgesia: potential long-term therapy for chronic pain
    Till A Röhn
    Cytos Biotechnology AG, Immunodrugs, Zurich, Switzerland
    J Immunol 186:1769-80. 2011
    ..Thus, autovaccination targeting NGF using a VLP-based approach may represent a novel modality for the treatment of chronic pain...
  7. doi Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study
    Alain C Tissot
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    Lancet 371:821-7. 2008
    ..Immunisation against angiotensin II could solve this problem. We investigated the safety and efficacy of CYT006-AngQb-a vaccine based on a virus-like particle-that targets angiotensin II to reduce ambulatory blood pressure...
  8. ncbi The coming of age of virus-like particle vaccines
    Gary T Jennings
    Cytos Biotechnology AG, CH 8952 Zurich Schlieren, Switzerland
    Biol Chem 389:521-36. 2008
    ..During the last decade, two prophylactic virus-like particle vaccines have been registered for human use, while another 12 vaccines entered clinical development...
  9. doi A VLP-based vaccine against interleukin-1α protects mice from atherosclerosis
    Alain C Tissot
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    Eur J Immunol 43:716-22. 2013
    ..In summary, vaccination against IL-1α protected ApoE(-/-) mice against disease, suggesting that this may be a potential treatment option for atherosclerosis...
  10. ncbi A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity
    Patrik Maurer
    Cytos Biotechnology AG, Zurich, Switzerland
    Eur J Immunol 35:2031-40. 2005
    ..These data suggest that antibodies induced by NicQb may prevent relapses by sequestering nicotine in the blood of immunized smokers...
  11. pmc Versatile virus-like particle carrier for epitope based vaccines
    Alain C Tissot
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    PLoS ONE 5:e9809. 2010
    ..Virus-like-particles are a very efficient means to confer high immunogenicity to antigens. We report here the development of virus-like-particles (VLPs) derived from the RNA bacteriophage AP205 for epitope-based vaccines...
  12. pmc Bacterially produced recombinant influenza vaccines based on virus-like particles
    Andrea Jegerlehner
    Immunodrugs Department, Cytos Biotechnology AG, Schlieren, Zurich, Switzerland
    PLoS ONE 8:e78947. 2013
    ..Moreover vaccination with these vaccines induced full protection against lethal challenges with homologous and highly drifted influenza strains. ..
  13. ncbi A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis
    Gunther Spohn
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    J Immunol 178:7450-7. 2007
    ....
  14. doi Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
    Martin F Bachmann
    Research, Cytos Biotechnology AG, Wagistrasse 25, 8952 Schlieren Zürich, Switzerland
    Nat Rev Immunol 10:787-96. 2010
    ..In this Review, we discuss the approaches currently being used to optimize the delivery of antigens and enhance vaccine efficacy...
  15. ncbi Designing recombinant vaccines with viral properties: a rational approach to more effective vaccines
    Gary T Jennings
    Cytos Biotechnology AG, Wagistr 25, 8952 Zurich Schlieren, Switzerland
    Curr Mol Med 7:143-55. 2007
    ..Vaccines which, by way of rational design, incorporate viral properties to induce tailored responses and thus have the potential to provide safer and more effective prophylaxis and therapies...
  16. ncbi Virus-like particles as a modular system for novel vaccines
    Franziska Lechner
    Cytos Biotechnology AG, Zurich, Switzerland
    Intervirology 45:212-7. 2002
    ..Using this method, efficient antibody responses may be induced in the absence of adjuvants resulting in protection from viral infection and allergic reactions...
  17. ncbi Immunotherapies: cause for measured optimism
    Gary T Jennings
    Cytos Biotechnology AG, Wagistr 25, CH 8952 Schlieren Zurich, Switzerland
    Drug Discov Today 7:994-6. 2002
  18. ncbi Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis
    Till A Röhn
    Cytos Biotechnology AG, Immunodrugs, Zurich, Switzerland
    Eur J Immunol 36:2857-67. 2006
    ..Active immunization against IL-17 therefore represents a novel therapeutic approach for the treatment of chronic inflammatory diseases...